ArticleCurrent developments in nutrition2025
A Hitchhiker Story? Exploring HDL as an Overlooked Vitamin D Carrier.
Article in Current developments in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Profiling Cardiovascular Disease-Associated Changes in the Composition of High-Density Lipoprotein Particles.Cardiovascular drugs and therapy · 2026Review
- Vitamin D and the aging skin: insights into oxidative stress, inflammation, and barrier function.Immunity & ageing : I & A · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Twenty-five-hydroxyvitamin D, used to assess vitamin status, is the primary circulating form of vitamin D having a half-life measured in weeks, and 1,25-dihydroxyvitamin D is the active metabolite having a half-life measured in hours. Although there has been a preponderance of research on the roles of the active metabolite in health, there remains a limited understanding of the transport of the true vitamin forms, ergocalciferol and cholecalciferol. Objective: This study proposes an alternative mechanism for vitamin D transport, hypothesizing that high-density lipoprotein (HDL) facilitates its movement from the intestine to the liver using cholesterol transporters. Methods: This perspective challenges the sole reliance on the classical chylomicron pathway, proposing an alternative mechanism based on vitamin D's striking structural similarity to cholesterol. Both are steroids sharing key features, suggesting analogous intestinal absorption and transport routes. Evidence indicates vitamin D utilizes known enteric cholesterol transporters for uptake. We hypothesize that high-density lipoprotein (HDL) functions as an important interorgan carrier, facilitating vitamin D's movement from the intestine to the liver, using shared cholesterol transporters. This proposed HDL-mediated delivery is particularly relevant given vitamin D-binding protein's lower affinity for vitamin D compared with 25-hydroxyvitamin D. Results: This mechanism offers a plausible explanation for observed correlations between vitamin D status (plasma 25-hydroxyvitamin D concentrations) and factors affecting HDL cholesterol concentration (HDLc). Modulators that increase HDLc (e.g., fibrates, oral contraceptives, and exercise) are associated with improved vitamin D status, whereas those that decrease HDLc or inhibit vitamin D absorption (e.g., smoking and ezetimibe) are linked to lower vitamin D status. Although current human data are largely correlative and confounded by numerous factors affecting vitamin D status, the consistent associations warrant further investigation into vitamin D's precise trafficking among lipoprotein fractions. Conclusions: Re-evaluating vitamin D's absorption and transport to include a role for HDL holds implications for optimizing vitamin D status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.